ArticleMolecular systems biology2021
Engineering a genome-reduced bacterium to eliminate Staphylococcus aureus biofilms in vivo.
Article in Molecular systems biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 46 citations in OpenAlex.
- Engineered bacteria in disease diagnosis and therapy: A synthetic biology perspective.Synthetic and systems biotechnology · 2026Review
- Opportunities for artificial intelligence and synthetic biology in designing living drug delivery systems.Advanced drug delivery reviews · 2026Review
- Living Microbial Drugs.Chemistry (Weinheim an der Bergstrasse, Germany) · 2026Review
- Nucleoside binding by a surface lipoprotein governs conjugative ICE acquisition in mycoplasmas.mBio · 2026Article
- Engineered Mycoplasma pneumoniae targeting dual-species bacterial biofilms: a novel strategy against infections.NPJ biofilms and microbiomes · 2025Article
- A versatile plug and play bacterial chassis based on a fast-growing Mycoplasma species.Nucleic acids research · 2025Article
- Review
- Review
- Developing anACS pharmacology & translational science · 2025Article
- Bacterial live therapeutics for human diseases.Molecular systems biology · 2024Review
- Heterologous protein exposure and secretion optimization in Mycoplasma pneumoniae.Microbial cell factories · 2024Article
- Pharmacological Innovations in Space: Challenges and Future Perspectives.Pharmaceutical research · 2024Review
- Review
- Functional surface expression of immunoglobulin cleavage systems in a candidate Mycoplasma vaccine chassis.Communications biology · 2024Article
- From Gene Editing to Biofilm Busting: CRISPR-CAS9 Against Antibiotic Resistance-A Review.Cell biochemistry and biophysics · 2024Review
- Engineered microorganisms: A new direction in kidney stone prevention and treatment.Synthetic and systems biotechnology · 2024Review
- Developing a platform for secretion of biomolecules in Mycoplasma feriruminatoris.Microbial cell factories · 2024Article
- Engineering bacterial theranostics: from logic gates toFrontiers in bioengineering and biotechnology · 2024Review
- Application of Protein Expression inScientifica · 2024Review
- The Bacterial Biofilms: Formation, Impacts, and Possible Management Targets in the Healthcare System.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2024Review
Corrections and comments
- Commented on by
Authors and funding
13 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacteria present a promising delivery system for treating human diseases. Here, we engineered the genome-reduced human lung pathogen Mycoplasma pneumoniae as a live biotherapeutic to treat biofilm-associated bacterial infections. This strain has a unique genetic code, which hinders gene transfer to most other bacterial genera, and it lacks a cell wall, which allows it to express proteins that target peptidoglycans of pathogenic bacteria. We first determined that removal of the pathogenic factors fully attenuated the chassis strain in vivo. We then designed synthetic promoters and identified an endogenous peptide signal sequence that, when fused to heterologous proteins, promotes efficient secretion. Based on this, we equipped the chassis strain with a genetic platform designed to secrete antibiofilm and bactericidal enzymes, resulting in a strain capable of dissolving Staphylococcus aureus biofilms preformed on catheters in vitro, ex vivo, and in vivo. To our knowledge, this is the first engineered genome-reduced bacterium that can fight against clinically relevant biofilm-associated bacterial infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.